Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from COSCIENS Biopharma ( (TSE:CSCI) ) is now available.
On May 12, 2026, COSCIENS Biopharma reported first-quarter results showing a sharp swing to consolidated net income of $10.8 million, or $3.42 per share, versus a $3.7 million loss a year earlier, driven largely by $10.9 million of income from discontinued operations tied to the deconsolidation of its insolvent German subsidiaries. Revenue rose to $1.9 million and operating expenses halved to $1.5 million, while net loss from continuing operations narrowed to $0.2 million as the company cut selling, general and administrative costs and reduced research and development spend.
The company detailed that its German units Aeterna Zentaris GmbH and Zentaris IVF GmbH filed for insolvency on March 23, 2026, with control effectively ending March 27, and their results are now treated as discontinued operations. COSCIENS also set June 17, 2026, for a shareholder meeting to consider a share reorganization aimed at enabling a suspension of U.S. SEC reporting obligations, and confirmed it will not advance its AvenActive inflammation program after Phase 2a results failed to show statistically significant benefits, underscoring a broader shift toward cost savings and a streamlined portfolio.
More about COSCIENS Biopharma
COSCIENS Biopharma Inc. is a holding company whose main operating arm, Ceapro Inc., develops and commercializes natural, plant-based active ingredients derived from oats and other renewable resources. Leveraging proprietary extraction and manufacturing technologies, Ceapro supplies these ingredients for personal care, cosmetic, and human and animal health markets, and COSCIENS’ shares trade on the TSX and OTCQB.
The company focuses on natural products and innovative delivery systems aimed at value-added applications across health and wellness-oriented industries.
Average Trading Volume: 4,366
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$8.25M
For a thorough assessment of CSCI stock, go to TipRanks’ Stock Analysis page.